Mohit Bansal
Stock Analyst at Wells Fargo
(0.48)
# 1972
Out of 5,234 analysts
159
Total ratings
51.76%
Success rate
5.72%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Summit Therapeutics | Initiates Coverage On: Overweight | 30 | n/a | n/a | 1 | Dec 11, 2024 | |
BioNTech | Initiates Coverage On: Overweight | 170 | 120.13 | 41.51% | 1 | Dec 11, 2024 | |
Vera Therapeutics | Initiates Coverage On: Overweight | 70 | 42.26 | 65.64% | 1 | Nov 21, 2024 | |
Gilead Sciences | Maintains: Overweight | 100 105 | 91.03 | 15.35% | 9 | Nov 7, 2024 | |
Merck & Co | Maintains: Equal-Weight | 125 110 | 99.73 | 10.3% | 10 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 1200 1050 | n/a | n/a | 15 | Oct 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 9 27 | 18.7 | 44.39% | 4 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 58 62 | 50.46 | 22.87% | 5 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 115 90 | 67.02 | 34.29% | 5 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 14 12 | 4.5 | 166.67% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 875 1000 | 764.03 | 30.88% | 15 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 320 335 | 257.65 | 30.02% | 8 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 240 225 | 153.15 | 46.91% | 11 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 140 120 | 121.67 | -1.37% | 1 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 28 30 | 26.88 | 11.61% | 9 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 200 205 | 179.81 | 14.01% | 6 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 540 555 | 402.51 | 37.88% | 8 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 140 170 | n/a | n/a | 7 | Apr 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 51 52 | 56.68 | -8.26% | 7 | Apr 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 30 40 | n/a | n/a | 1 | Aug 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 30 | n/a | n/a | 3 | May 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 27 | 13.05 | 106.9% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 50 | n/a | n/a | 1 | Nov 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 60 | n/a | n/a | 1 | Jun 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 1875 | 22.6 | 8196.46% | 1 | Mar 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 35 | n/a | n/a | 1 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 25 30 | 14.75 | 103.39% | 4 | Jan 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 175 | n/a | n/a | 1 | Dec 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 36 | n/a | n/a | 1 | Nov 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 125 225 | n/a | n/a | 4 | Oct 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 16 19 | 21.89 | -13.2% | 3 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 8 5 | 0.65 | 669.23% | 3 | Apr 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 160 140 | n/a | n/a | 2 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Neutral | 30 60 | 2.7 | 2122.22% | 4 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 100 116 | n/a | n/a | 2 | Oct 2, 2017 |